NovaBridge Biosciences’ latest SEC disclosures reveal a critical regulatory milestone with the FDA Fast Track designation granted to givastomig for first-line HER2-negative metastatic gastric cancer. This regulatory recognition underscores growing clinical validation for its oncology pipeline. Concurrently, the company announced dismissal of PricewaterhouseCoopers as auditors and onboarding Deloitte, reflecting continuing efforts to remediate material weaknesses in internal control over financial reporting, particularly information technology general controls. NovaBridge’s diversified biologics portfolio anchored by collaborations such as its global partnership with AbbVie supports its R&D-driven licensing revenue model. The company maintains a strong cash position exceeding $210 million, underpinning its sustained clinical development and operational runway. However, investor attention should remain attentive to execution risks in internal control reform and pivotal upcoming clinical milestones.